What is Replacing Tysabri? Understanding Alternatives in MS Treatment
•
4 min read
In August 2023, the FDA approved Tyruko, the first biosimilar for Tysabri, signaling a major shift in multiple sclerosis (MS) treatment. As medical understanding evolves, patients and healthcare providers are considering new therapeutic options and weigh the risks and benefits of continuing or discontinuing older medications like Tysabri, which carries the risk of the brain infection PML.
